Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the grant of 48,731 restricted stock units (RSUs) to 26 newly hired non-executive employees. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, effective June 16, 2025. The RSUs will vest over a four-year period, with 25% of shares vesting annually on each grant date anniversary. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement for new hires. Ultragenyx, which focuses on developing and commercializing therapies for rare and ultra-rare diseases, uses these equity awards to attract and retain talent.

NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

How many restricted stock units did Ultragenyx (RARE) grant to new employees in June 2025?

Ultragenyx granted 48,731 restricted stock units to 26 newly hired non-executive employees.

What is the vesting schedule for Ultragenyx's June 2025 RSU grants?

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the June 16, 2025 grant date.

Under which plan were the Ultragenyx (RARE) RSUs granted in June 2025?

The RSUs were granted under the Ultragenyx Employment Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

What is the purpose of Ultragenyx's RSU grants announced in June 2025?

The RSUs were granted as an inducement material to attract new employees entering into employment with Ultragenyx.